Triumvira expands management team

, , ,

Triumvira Immunologics has appointed Sabine Chlosta, M.D., Ph.D., as chief medical officer and Jon Irvin as VP of finance.

“We are delighted to expand our executive management team with Dr. Chlosta and Mr. Irvin,” says Paul Lammers, M.D., M.Sc., president and CEO of Triumvira Immunologics. “We look forward to leveraging Sabine’s extensive experience in immuno-oncology and clinical trial oversight as we work to develop and commercialize innovative therapies that will empower a patient’s own immune system to tackle serious and life-threatening diseases.

“In addition, Jon’s finance expertise in the pharmaceutical and technology industries will be a strong asset to Triumvira as we build our company to bring new treatments to patients in need.”

Before joining Triumvira, Dr. Chlosta consulted for Aurora BioPharma, a start-up company developing CAR-T cells in solid tumors and was previously a senior medical director at Merck & Co. where she played a key role in the development of its PD-1 inhibitor Keytruda in non-Hodgkin’s lymphoma and oversaw trials in other indications as well. Earlier in her career, Dr. Chlosta was a medical director at Glycomimetics where she helped launch the company’s first trial in cancer. She began her industry career as a fellow in Oncology Drug Development at Novartis overseeing clinical pharmacology trials with a small molecule and helped launch its CAR-T lymphoma program with Kymriah. Dr. Chlosta is a board-certified pediatric hematologist oncologist out of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College.

“Triumvira is poised for growth and success in T cell therapy, and I am thrilled to be part of the team to take our innovative TAC technology into the clinic,” Dr. Chlosta says.

Jon Irvin

Irvin was the chief financial officer and VP of finance at Mirna Therapeutics, a publicly traded biotechnology company, before joining Triumvira. He also served in executive financial positions for Voxpath Networks Inc., a telecommunications and intellectual property company; Reddwerks Corp., a software company; Esoterix Inc., a medical laboratory company; Topaz Technologies, a pharmaceutical software company; and BioNumerik Pharmaceuticals Inc., a  pharmaceutical company. Irvin previously worked with Ernst & Young’s life science practice in Palo Alto, Calif.

“It’s exciting to be a part of this growing team as we develop our novel platform to treat patients’ unmet medical needs,” Irvin says.

Triumvira Immunologics is an immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Operations span North America, with corporate offices located in Austin, Texas, and research facilities in Hamilton, Ontario.